Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

BJOG : an international journal of obstetrics and gynaecology - 1 Mar 2011

Mukhopadhyay A, Curtin N, Plummer R, Edmondson R J

Abstract excerpt

Poly-ADP ribose polymerase (PARP) inhibitors have emerged as exciting new chemotherapy options for women with ovarian cancer. They exploit a mechanism known as synthetic lethality by targeting specific DNA repair pathways. Recent Phase II clinical trials have shown great promise in treating women with hereditary breast and ovarian cancers associated with BRCA1/2 mutations. Most importantly, they appear to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Chemoprevention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forecasting

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasms, Glandular and Epithelial

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Precision Medicine

Source

Identifiers

PMID: 21244617
DOI: 10.1111/j.1471-0528.2010.02838.x

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.PMID 21244617Read ↗

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Semantic proximity Read ↗

PARP inhibitors: A new era of targeted therapy.Semantic proximity Read ↗

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian CancerSemantic proximity Read ↗

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Semantic proximity Read ↗

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read ↗

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future DevelopmentSemantic proximity Read ↗

New treatment option for ovarian cancer: PARP inhibitorsSemantic proximity Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.